Recorded Presentation from the NCCN Pharmacy Updates: The Role of Tyrosine Kinase Inhibitors in Pediatric Acute Lymphoblastic Leukemia
English
Recorded Courses
hosted by National Comprehensive Cancer Network (NCCN)
hosted by National Comprehensive Cancer Network (NCCN)
attend it anywhere online
category
Medicine, Nursing, Pharmacy, Healthcare Management
Nurse Practitioners, Oncology, Hematology
price
Free
Recorded Presentation from the NCCN Pharmacy Updates: The Role of Tyrosine Kinase Inhibitors in Pediatric Acute Lymphoblastic Leukemia is organized by National Comprehensive Cancer Network (NCCN).,Description:,Although therapy with tyrosine kinase inhibitors (TKIs) has been a common adoption in cancer treatment of Ph+ ALL, further research has helped expand the understanding of the role and limitations of these very agents, which now also play a major role in the treatment of the Ph-like ALL subtype. It is important for healthcare professionals caring for pediatric patients with ALL to recognize aspects of optimal dosing and frequency, appropriate use in particular genomic alterations, mechanisms of resistance, and patient-specific counseling points to ensure efficacy and compliance of TKIs.,Learning Objectives:,Following this activity, participants should be able to:,• Summarize the initial presentation, diagnostic criteria, and risk stratification of pediatric acute lymphoblastic leukemia (ALL).,• Describe the genomic alterations of pediatric Philadelphia chromosome-positive (Ph+) and Philadelphia chromosome-like (Ph-like) ALL.,• Distinguish the role, impact, and potential limitations of tyrosine kinase inhibitors in the treatment of pediatric Ph+ and Ph-like ALL.,Additional details will be posted as soon as information is available.